Literature DB >> 12973448

Pharmacological inactivation of MYC for the treatment of cancer.

Dean W Felsher1, Nicole Bradon.   

Abstract

The overexpression of the MYC proto-oncogene has been implicated in the pathogenesis of most types of human cancer. Recent experimental observations indicate that the inactivation of MYC may be effective in the treatment of neoplasia. Several different strategies have been employed to develop novel drugs that may be effective to target the inactivation of MYC for the treatment of cancer. Some of these strategies are discussed. (c) 2003 Prous Science. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12973448     DOI： 10.1358/dnp.2003.16.6.829309

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN： 0214-0934


  5 in total

1.  Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation.

Authors:  Hao Mo; Marie Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

2.  Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma.

Authors:  Karina Galoian; Thomas H Temple; Armen Galoyan
Journal:  Neurochem Res       Date:  2011-01-18       Impact factor: 3.996

3.  Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.

Authors:  Karina Galoian; Sean Scully; Armen Galoyan
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

4.  Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma.

Authors:  Karina Galoian; Sean Scully; George McNamara; Patrick Flynn; Armen Galoyan
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

5.  Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.

Authors:  Stella Pelengaris; Sylvie Abouna; Linda Cheung; Vasiliki Ifandi; Sevasti Zervou; Michael Khan
Journal:  BMC Biol       Date:  2004-12-21       Impact factor: 7.431
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.